Published in Health Business Week, November 18th, 2005
"An 18-month randomized double-blind study in postmenopausal women with osteoporosis was conducted" by scientists in France "to compare the effects of once-daily teriparatide 20 mcg with alendronate 10 mg on bone histomorphometry. Biopsies were obtained from 42 patients. Indices of bone formation were significantly higher after 6 to 18 months of teriparatide compared with alendronate treatment. Alendronate and teriparatide increased BMD, assessed by DXA, by different mechanisms of action, supported by changes in biochemical markers of bone turnover."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week